Lataa...
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma
Anti-angiogenic therapy is a promising therapeutic strategy for the highly vascular and malignant brain tumor, glioblastoma (GBM), although current clinical trials have failed to demonstrate an extension in overall survival. The small molecule tyrosine kinase inhibitor axitinib that targets vascular...
Tallennettuna:
| Julkaisussa: | J Neurooncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751887/ https://ncbi.nlm.nih.gov/pubmed/25213669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1612-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|